Literature DB >> 18480836

How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance.

T Zenz, S Häbe, T Denzel, D Winkler, H Döhner, S Stilgenbauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18480836     DOI： 10.1038/leu.2008.114

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

2.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Hossein Khiabanian; Valeria Spina; Carmela Ciardullo; Alessio Bruscaggin; Rosella Famà; Silvia Rasi; Sara Monti; Clara Deambrogi; Lorenzo De Paoli; Jiguang Wang; Valter Gattei; Anna Guarini; Robin Foà; Raul Rabadan; Gianluca Gaidano
Journal:  Blood       Date:  2014-02-05       Impact factor: 22.113

Review 3.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

4.  First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.

Authors:  Carmen Diana Schweighofer; Clemens-Martin Wendtner
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

Review 5.  What do we do with chronic lymphocytic leukemia with 17p deletion?

Authors:  L Sellner; S Denzinger; S Dietrich; H Glimm; O Merkel; P Dreger; T Zenz
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

6.  Latexin sensitizes leukemogenic cells to gamma-irradiation-induced cell-cycle arrest and cell death through Rps3 pathway.

Authors:  Y You; R Wen; R Pathak; A Li; W Li; D St Clair; M Hauer-Jensen; D Zhou; Y Liang
Journal:  Cell Death Dis       Date:  2014-10-23       Impact factor: 8.469

Review 7.  ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Authors:  J Malcikova; E Tausch; D Rossi; L A Sutton; T Soussi; T Zenz; A P Kater; C U Niemann; D Gonzalez; F Davi; M Gonzalez Diaz; C Moreno; G Gaidano; K Stamatopoulos; R Rosenquist; S Stilgenbauer; P Ghia; S Pospisilova
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

Review 8.  Impact of Low-Burden TP53 Mutations in the Management of CLL.

Authors:  Gregory Lazarian; Florence Cymbalista; Fanny Baran-Marszak
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.